澳大利亚生物技术公司 Orthocell 推进 FDA 对神经修复产品 Remplir™ 的批准。 Australian biotech firm Orthocell advances FDA approval for nerve repair product Remplir™.

澳大利亚生物技术公司Orthocell公司在林业发展局批准RemplirTM(一种旨在治疗外围神经外伤的神经修复产品)的过程中达到了一个关键里程碑。 Australian biotech firm Orthocell has reached a key milestone in its FDA approval process for Remplir™, a nerve repair product aimed at treating peripheral nerve injuries. 该公司已经完成了一项关键研究的患者入学阶段,进入临床试验的下一个阶段。 The company has completed the patient enrollment phase of a critical study, advancing toward the next stages of clinical trials. 这一进展使Orthocell公司更接近于利用天然的、以科林为基础的办法为神经损伤患者提供新解决办法的可能性。 This progress moves Orthocell closer to potentially providing a new solution for nerve damage patients, using a natural, collagen-based approach.

文章

Proactive Investors Australia

Proactive Investors

Proactive Investors Australia

Proactive Investors

Proactive Investors

-- 显示更少 --

延伸阅读

相关故事